Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Delhi HC Upholds...

Delhi HC Upholds AstraZeneca's Tagrisso Patent, Imposes Rs 7L Fine on 'Habitual Infringer' for Knockoff Production

Farhat NasimWritten by Farhat Nasim Published On 2024-12-02T16:48:15+05:30  |  Updated On 2 Dec 2024 4:48 PM IST
AstraZeneca Imfinzi recommended for approval in EU for adults with muscle-invasive bladder cancer
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: In a major relief to AstraZeneca, the Delhi High Court has granted summary judgment, confirming that Westcoast Pharmaceutical Works Ltd. infringed AstraZeneca's patent for its cancer drug Osimertinib. The court has imposed a fine of Rs 7,00,000 on Westcoast Pharmaceutical and directed the company to cease manufacturing, marketing, or distributing Osimertinib (Tagrisso).

The patent (IN 297581) protects the drug’s composition and grants AstraZeneca exclusive rights to manufacture and sell Osimertinib in India until 2032.

AstraZeneca’s patented compound, Osimertinib, is used to treat specific types of non-small cell lung cancer (NSCLC) and is marketed under the brand name Tagrisso. The drug has received regulatory approval in India and is widely used for treating cancer with certain mutations.

The case began when AstraZeneca discovered that Westcoast Pharmaceutical was offering to manufacture Osimertinib in bulk, despite the drug being protected by AstraZeneca’s patent. The company was actively marketing the drug in India via flyers, offering to supply up to 1,00,000 tablets. The infringement was brought to light in early 2022, prompting AstraZeneca to file a lawsuit.

In response, the court issued an ex parte ad interim injunction on February 11, 2022, barring Westcoast from selling or manufacturing the drug. Despite being notified of the proceedings, Westcoast failed to file a written statement within the prescribed time of 120 days, which led the court to rule that the defendant had no legitimate defense. Consequently, the court made the interim injunction permanent on November 30, 2022.

Westcoast Pharmaceutical attempted to justify its actions in an affidavit, stating that the regulatory approval for Osimertinib was obtained under the belief that it was not patented in India. They also claimed they had not manufactured the drug and had filed for cancellation of the approval in August 2022. However, the court held the company accountable, citing its failure to comply with the legal process and its history of intellectual property violations in other cases.

The court also acknowledged the defendant's history of patent infringements, including past legal disputes over other patented drugs like Dapagliflozin, where they were previously restrained from selling the drug due to patent violations. The court noted that Westcoast’s pattern of infringing intellectual property rights raised serious concerns about its credibility and intent. It remarked;

“It is submitted that the Defendant is a habitual infringer, with a history of infringing upon the intellectual property rights of various patent holders. Evidence of the Defendant's prior infringements, as documented in previous cases, clearly establishes a pattern of unlawful behaviour. It is submitted that the Defendant, on its website claims to be to be in the business of pharmaceuticals since 1965. It further boasts that it has a strong oncology division and that it exports its products on a large scale. It is submitted that it is not possible for the Defendant to have not known about the Plaintiffs, its Indian patent [IN'581] and the availability of its products in India.”
“The Defendant has been involved in multiple litigations before this Hon'ble Court wherein it has submitted to the jurisdiction of this Hon'ble Court and where this Hon'ble Court has found it to be guilty of similar infringing activities.”

The court found that the defendant had no credible defense. Despite multiple opportunities to respond, the defendant failed to file a written statement within the required timeframe, thus forfeiting its right to do so. The court concluded that there was no valid argument or evidence presented by the defendant that could justify a trial. In the absence of any legitimate defense, the court ruled that the case was suitable for summary judgment, a legal procedure that allows for a quicker resolution of disputes without the need for a full trial.

It noted;

“In view of the aforesaid undertaking of the defendant and the fact that no written statement has been filed by the defendant, it is manifest that there is no defence raised by the defendant. In the absence of any credible defence, and in the absence of any argument or evidence by the defendant that could justify a trial, it is held that the present is a fit case for passing summary judgment. Accordingly, it is held that the plaintiff is entitled to decree in its favour.”

Subsequently, the court recognized the infringement and issued a summary judgment in favor of AstraZeneca, granting a permanent injunction to prevent the defendant from manufacturing or selling the drug Osimertinib.

The court also ruled that AstraZeneca was entitled to a cost award of Rs 7,00,000 to cover the legal expenses incurred due to the defendant's delays and frivolous applications.

To view the original order, click on the link below:

https://indiankanoon.org/doc/182933814/

westcoast pharmaceutical worksdelhi high courtpatent infringementosimertinibtagrissodapagliflozincancerastrazeneca
Farhat Nasim
Farhat Nasim

    Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    View All

    Journal Club Today

    Study Reveals Why Your Immune System Works Better in Daylight

    Study Reveals Why Your Immune System Works Better in Daylight

    View All

    Health News Today

    Health Bulletin 30/May/2025

    Health Bulletin 30/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok